Susquehanna International Group’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Susquehanna International Group’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,180	Closed	-$71K	–	14199
2021 Q4	$71K	Sell	1,180 -1,260	-52%	-$94.3K	﹤0.01%	12372
2021 Q3	$229K	Buy	+2,440	New	+$325K	﹤0.01%	11193

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Susquehanna International Group's TLIS Position: Q3 2024 in Review

Susquehanna International Group sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 11,607 shares — an estimated $102K sold.

Susquehanna International Group first reported a position in TLIS in Q4 2021 and held it in 9 quarters. The position peaked at $153K in Q1 2024. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

Susquehanna International Group reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
Susquehanna International Group sold 11,607 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $102K.
Susquehanna International Group first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and held it in 9 quarters.
Susquehanna International Group's Talis Biomedical Corporation Common Stock position peaked at $153K in Q1 2024.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.